(AOF) – Transgene announces a partnership with NEC Corporation, a Japanese specialist in information technologies, networks and artificial intelligence (AI), relating to the continued clinical evaluation of the individualized neoantigenic cancer vaccine TG4050. The biotech focused on immunotherapies based on viral vectors against cancers is preparing with Nec a new randomized trial of its product, adjuvant treatment of head and neck cancers. TG4050 comes from Transgene’s myvac platform.
TG4050 benefits from NEC’s artificial intelligence technologies for the identification and prediction of the most immunogenic neoantigens.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
